Patient perspectives on SLE, refractory APS, and biologic drug use during pregnancy

Read full text Summarise with VIRAT
Authors: Jara van Woerkom, Merlijn Wind, Yoe Kie Onno Teng, A. Titia Lely, Jamy Pullen, Gerard AJG Jansen, Luis Fernando Pérez-García, R. Dolhain, Maarten Limper, Judith Kooiman
Cited by: 0
References: 26

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

PurposeWomen with Systemic Lupus Erythematosus (SLE) and/or Antiphospholipid Syndrome (APS) have an increased risk of pregnancy complications. This study explored their perspectives on pregnancy, pregnancy complications, and medication use during pregnancy.MethodsIn collaboration with the Dutch National Patient Association for Lupus Erythematosus, an online questionnaire was developed and distributed among female members. The questionnaire presented eight potential pregnancy complication scenarios. Respondents indicated whether they found the standard medication regime sufficient and their willingness to take additional medication. They also assessed which side effects of biological therapies would discourage additional treatment. The survey ran from November 18, 2023, to March 19, 2024.Major findingsOf 71 respondents (mean age 39), 42% had APS, 31% had SLE, and 27% had both. A majority (79%) would endure pregnancy complications, such as SLE flare or pre-eclampsia, if it meant a live-born baby. Willingness to use additional medication varied by scenario (51%-89%) depending on the specific complication at risk. Most side effects associated with the use of biologicals were deemed acceptable by the majority of respondents. However, a slight majority indicated they would refrain from additional medication if it led to an increased risk of infections such as urinary tract infections or pneumonia.ConclusionMost women would accept adverse obstetric outcomes or maternal complications as long as pregnancy results in a live birth. The majority of respondents consistently expressed a desire for additional medication to reduce the risk of complications during pregnancy, regardless of the specific complication at hand.

Fields of Study & Subjects

Pregnancy and Medication Impact Systemic Lupus Erythematosus Research Cardiovascular Issues in Pregnancy

Publication details

Journal / source
Lupus
Volume
35
Issue
7
Pages
699–708
Publication date
26 March 2026
Language
EN